title: Resolvins RvD1 and 17(R)-RvD1 alleviate signs of inflammation in a rat model of endometriosis.
abstract: OBJECTIVE
  To study the effects of two resolvins of D series, RvD1 and 17(R)-RvD1, on inflammatory signs associated with endometriosis (ENDO).
  
  
  METHODS
  In vivo research study.
  
  
  METHODS
  Research laboratory.
  
  
  METHODS
  Female Sprague-Dawley rats.
  
  
  METHODS
  Intravenous or intraperitoneal injections of RvD1 (300 ng/kg) or 17(R)-RvD1 (300 and 900 ng/kg) in rats with surgically induced ENDO.
  
  
  METHODS
  Vascular permeability of ectopic endometrial growths was assessed by Evans Blue extravasation; vaginal hyperalgesia was assessed with telemetered visceromotor response.
  
  
  RESULTS
  Both resolvins, but not vehicle, significantly decreased vascular permeability in ectopic endometrial tissue. 17(R)-RvD1 also significantly alleviated severity of vaginal hyperalgesia.
  
  
  CONCLUSIONS
  Our results suggest that RvD1 and 17(R)-RvD1 can be considered for further investigation of their therapeutic potential for treating ENDO.
authors.affiliation: Program in Neuroscience, Florida State University, Tallahassee, Florida. Electronic address: dmitrieva@psy.fsu.edu.
authors.forename: Natalia
authors.initials: N
authors.lastname: Dmitrieva
authors.affiliation: Program in Neuroscience, Florida State University, Tallahassee, Florida.
authors.forename: Gregory
authors.initials: G
authors.lastname: Suess
authors.affiliation: Program in Neuroscience, Florida State University, Tallahassee, Florida.
authors.forename: Russell
authors.initials: R
authors.lastname: Shirley
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002199:Capillary Permeability / Q000187:drug effects; D004195:Disease Models, Animal; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D004715:Endometriosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D006930:Hyperalgesia / Q000503:physiopathology / Q000517:prevention & control; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D017288:Pain Threshold / Q000187:drug effects; D017207:Rats, Sprague-Dawley; D012720:Severity of Illness Index; D014621:Vagina / Q000294:innervation
chemical_list: D000893:Anti-Inflammatory Agents; C518399:resolvin D1; D004281:Docosahexaenoic Acids
keywords: Proresolving lipid mediator; cyclo-oxygenase 2; docosahexaenoic acid; endometrium; hyperalgesia; omega-3 polyunsaturated fatty acid